摘要
近年来,针对PD-1及PD-L1的研究深入,免疫治疗逐渐兴起,但其在实体肿瘤患者中有效率只有20%左右,如何选择受益人群成为研究者面临的首要问题。最新临床研究表明循环肿瘤细胞(CTC)表面表达的PD-L1能够作为一种潜在的生物标志物,对恶性肿瘤的免疫治疗具有指导作用。本文将对CTC PD-L1在各种实体肿瘤中的表达情况及最新的临床研究进展作一综述。
In recent years,with the in-depth study of PD-1 and PD-L1 and the development of immunotherapy,the first problem is how to screen the beneficiaries.Recent clinical studies have shown that the expression level of PD-L1 in circulating tumor cells(CTC)can be used as a potential biomarker to play a guiding role in immunotherapy of malignant tumors.This article reviews the latest clinical research progress on the expression of PD-L1 in circulating tumor cells in various solid tumors.
作者
李祖曦
黄显斌
马云涛
詹渭鹏
狐鸣
田宏伟
杨婧
LI Zuxi;HUANG Xianbin;MA Yuntao;ZHAN Weipeng;HU Ming;TIAN Hongwei;YANG Jing(The First Clinical Medical College of Gansu University of Chinese Medicine,Lanzhou 730000,China;Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province,Gansu Provincial Hospital,Lanzhou 730000,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第3期225-229,共5页
Cancer Research on Prevention and Treatment
基金
甘肃省外科肿瘤分子诊断与精准治疗重点实验室开放基金(2019GSZDSYS06)
甘肃自然科学基金(21JR1RA017)
甘肃省人民医院内科研基金(21GSSYB-5)。
关键词
循环肿瘤细胞
液体活检
预后判断
疗效评估
免疫治疗监测
Circulating tumor cell
Liquid biopsy
Prognosis judgment
Efficacy evaluation
Immunotherapy monitoring
